QbCheck is a medical device that can be used for remote monitoring to provide health care professionals with objective measurements of hyperactivity, impulsivity, and inattention to aid in the clinical assessment of attention deficit hyperactivity disorder (ADHD). The aim of this investigation was to evaluate QbCheck administration results when used for remote monitoring of ADHD medication treatment. The dataset collected was from clinical routine QbCheck assessments at different clinical sites in the US, and data were stored in a database supplied by QbTech AB, Stockholm, Sweden. QbCheck was administered at baseline, prior to treatment and after ADHD medication treatment began. The sample population age range was between 7 and 60 years, 46% were females, and all subjects were diagnosed with ADHD (N=114). The average time between QbCheck assessments (baseline to follow- up) was 66 days (range 1-312 days). Per standard data collection of the QbCheck, five variables were captured and calculated to indicate measurements of inattention, impulsivity, and hyperactivity. A significant improvement from baseline to post-treatment follow-up was seen in all five parameters (Activity - MicroEventX, Impulsivity – Commission Error, and Attention – Omission Error, Reaction Time & Reaction Time Variance) which were associated with a significant reduction in QbCheck Total Symptom Score by 42.06%. These findings suggest that QbCheck is a useful objective measure that could be incorporated in guiding treatment decisions, remote monitoring of ADHD medication, tracking of ADHD symptom regulation, and optimizing treatment outcomes for those with ADHD.